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Research objects: Nucleophosmin is a multifunctional and widely expressed
phosphoprotein that mainly located in the nucleolus, and is involved in a variety of
cell activities, especially for cell survival, and the phenomenon of NPM
overexpression has been confirmed in many types of cancer. Liver fibrosis is a
long-term interaction with a variety of stimulating factors in the liver disease, and
its morbidity and mortality have an increasing trend in the world. However, there
is no clear conclusion about the molecular mechanism of hepatic fibrosis. This
paper is based on TGF-beta stimulates hepatic stellate cells to activate, therewith,
the expression of NPM and related liver fibrosis markers proteins such as ACTA2
were increased. Then, we studied the role of NPM in the development of hepatic
fibrosis and its preliminary molecular mechanism to provide theoretical basis for
exploring effective treatment of liver fibrosis.
Methods: Firstly, we studied the role of NPM in the development of liver fibrosis
by stimulating LX-2 cells with TGF-beta. Secondly, knockout or silence
endogenous NPM by CRISPAR-Cas9 /SiRNA, and verified by Western blot and
RT-qPCR. Finally, we used NSC348884 (NPM oligonucleotids inhibitor) and
MK2206 (AKT phosphorylation inhibitor) to stimulate LX-2 cells, and verify
whether NPM is involved in the development of liver fibrosis by Akt pathway.
Simultaneously, we detected the effect of inhibitor on reactive oxygen levels, cell
cycle and apoptosis by flow cytometry.
Results: TGF-beta stimulated LX-2 cells to activate, then NPM and ACTA2 gene
expression levels were increased, indicating that NPM involved in the occurrence
of liver fibrosis. During TGF-beta treat LX-2, p-AKT protein expression level also
increased. In knockout NPM expression of hepatic stellate cells, the expression of
liver fibrosis marker proteins such as ACTA2, Collagenand MMP9 are decrease













NSC348884 (NPM oligonucleotids inhibitor) and MK2206 (AKT phosphorylation
inhibitor) treated LX-2 cells, the expression levels of liver fibrosis marker proteins-
ACTA2, Collagenand MMP9 decreased with the reduction of NPM. In addition,
the level of the reactive oxygen species treated with TGF-beta in 5h have
significantly improved.
Conclusion: NPM is involved in the activation of hepatic stellate cells, which is the
central event of hepatic fibrosis, and plays a role in the development of hepatic
fibrosis. Knockout or silence NPM expression will inhibit the expression of hepatic
fibrosis marker (ACTA2, CollagenI and MMP9). NPM is likely involved in the
regulation of liver fibrosis through the Akt pathway.
Keywords: Nucleophosmin(NPM); Hepatic stellate cells; Akt pathway
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